Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Biogen (BIIB – Research Report). The associated price target ...

I'm 87 and whenever I do some weeding in my garden, I get really dizzy. I take losartan for my blood pressure and have ...

The facility at a business park in Raheen, Limerick, was first announced in 2022 and this is the second time that Lilly has ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

It's known that excessive use of earbuds at high volumes can cause hearing loss, so somewhat ironic that the FDA has just ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years.